Koutif Therapeutics today announced that its IND application for KT-1002 has been cleared by FDA to begin a Phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s Disease.
Koutif Therapeutics today announced that KT-1002, which has been selected as its lead compound, has reached clinical candidate status for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s Disease, after successfully completing IND-enabling studies.
SEPTEMBER 21, 2017
CLEVELAND AND PITTSBURGH - BioMotiv, a drug development accelerator, and the University of Pittsburgh announced the launch of Koutif Therapeutics, which is developing an inhibitor of an E3 ligase (Fbxo3) to treat inflammatory conditions such as neuropathic pain, COPD, lung transplant rejection, and irritable bowel disease.
Koutif Therapeutics is based on intellectual property licensed from the University of Pittsburgh and the United States Department of Veterans Affairs. The technology was developed by Rama K. Mallampalli, MD, a Harrington Scholar, and Beibei Chen, PhD.